文献速递血管炎

托珠单抗治疗巨细胞动脉炎的长期疗效:GiACTA试验开放标签延伸期

Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
PubMed 文献 · Lancet Rheumatol · 2021-03-19

GiACTA试验第二部分探索托珠单抗停药1年后的疗效维持、复发后再治疗及长期激素节省效应。215例入组,每周托珠单抗组59例停药者中42%在整个第二部分维持无药无激素临床缓解;3年累积泼尼松剂量每周托珠单抗组最低;复发后托珠单抗再治疗可恢复缓解,但需联用泼尼松以防视力丧失。

要点

  • 每周托珠单抗治疗1年后停药,42%患者在此后2年维持无药无激素缓解。
  • 3年累积泼尼松剂量每周托珠单抗组最低,优于安慰剂组。
  • 复发后再用托珠单抗可恢复缓解,但应联用泼尼松以防视力丧失。

核心结论

  • 巨细胞动脉炎仍需长期管理并警惕复发,但并非所有患者都需无限期免疫抑制治疗。
  • 相当比例患者接受托珠单抗治疗1年后可在停药后2年维持无药缓解。
  • 复发时可用托珠单抗治疗,但因视力丧失风险仍应联用泼尼松。

研究设计与样本

  • GiACTA试验第一部分将251例患者按2:1:1:1随机分配至每周或每两周皮下托珠单抗162 mg联合26周泼尼松减量、或安慰剂联合26周或52周泼尼松减量。
  • 第二部分为开放标签延伸期,治疗由研究者决定,可选用无治疗、托珠单抗、糖皮质激素、甲氨蝶呤或其组合,持续两年。

主要发现

  • 215例患者参与第二部分;第一部分随机分配至每周托珠单抗的81例中,59例在1年时临床缓解并停药进入第二部分。
  • 59例停药者中25例(42%)在整个第二部分维持无托珠单抗且无糖皮质激素的临床缓解。
  • 第二部分复发后接受治疗者中,托珠单抗单药(n=17)中位缓解时间15天,托珠单抗联合糖皮质激素(n=36)16天,单用糖皮质激素(n=27)54天。
  • 全程3年未报告新的或意外安全性发现。

关键数值与推荐

  • 临床缓解定义为研究者判定的无复发。
  • 维持疗效、累积糖皮质激素剂量和长期安全性为第二部分探索性目标。

临床怎么用

  • 对接受托珠单抗治疗1年达到缓解的巨细胞动脉炎患者,可考虑停药观察,因相当比例可维持无药缓解。
  • 复发时可用托珠单抗再治疗,但应联用泼尼松以降低视力丧失风险。

局限性

  • 第二部分为开放标签延伸期,治疗由研究者决定,非随机对照。
  • 维持疗效、累积激素剂量和长期安全性均为探索性目标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of tocilizumab plus a glucocorticoid taper is effective in maintaining clinical remission without requiring additional glucocorticoid therapy in patients with giant cell arteritis, as shown in part one of the Giant Cell Arteritis Actemra (GiACTA) trial. However, the duration of the tocilizumab effect after discontinuation is unknown. Here, we explored the maintenance of efficacy 1 year after discontinuation of tocilizumab treatment, the effectiveness of retreatment with tocilizumab after relapse, and the long-term glucocorticoid-sparing effect of tocilizumab. METHODS: In part one of the GiACTA trial, 251 patients were randomly assigned (2:1:1:1) to receive subcutaneous tocilizumab (162 mg) once a week or every other week, combined with a 26-week prednisone taper, or placebo combined with a prednisone taper over a period of either 26 weeks or 52 weeks. Patients in clinical remission stopped masked injections at 1 year (the conclusion of part one). In part two, treatment was at the investigators' discretion and could consist of no treatment, tocilizumab, glucocorticoids, methotrexate, or combinations of these, for two years. Maintenance of efficacy as assessed by clinical remission (defined as absence of relapse determined by the investigator), cumulative glucocorticoid dose, and long-term safety were exploratory objectives in part two of the trial. This trial is registered at ClinicalTrials.gov, NCT01791153. FINDINGS: 215 patients participated in part two of the trial; 81 patients who were randomly assigned to tocilizumab once a week in part one were in clinical remission after 1 year, of whom 59 started part two on no treatment. 25 of these 59 patients (42%) maintained tocilizumab-free and glucocorticoid-free clinical remission throughout part two. Median (95% CI) cumulative glucocorticoid doses over 3 years were 2647 mg (1987-3507) for tocilizumab once a week, 3948 mg (2352-5186) for tocilizumab-every-other-week, 5277 mg (3944-6685) for placebo with a 26-week prednisone taper, and 5323 mg (3900-6951) for placebo with a 52-week prednisone taper (van Elteren p≤0·001, tocilizumab once a week vs placebo groups; p<0·05, tocilizumab-every-other-week vs placebo groups). Tocilizumab-based regimens restored clinical remission among patients who experienced relapse in part two and were treated (median time to remission: 15 days for tocilizumab alone [n=17]; 16 days for tocilizumab plus glucocorticoids [n=36]; and 54 days for glucocorticoids alone [n=27]). No new or unexpected safety findings were reported over the full 3 years of the study. INTERPRETATION: Giant cell arteritis remains a chronic disease that entails ongoing management and careful vigilance for disease relapse, but continuous indefinite treatment with immunosuppressive drugs is not required for all patients. A substantial proportion of patients treated with tocilizumab for one year maintain drug-free remission during the two years after tocilizumab cessation. For patients who experience relapse, tocilizumab can be used to manage relapses, but it remains prudent to include prednisone for patients who experience relapse because of the risk for vision loss. FUNDING: F Hoffmann-La Roche.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Stone JH, Han J, Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021. PMID: 38279390. doi:10.1016/S2665-9913(21)00038-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。